Abstract
The falling cost of sequencing means that we are rapidly approaching an era in which access to personalized genomic information is likely to be widespread. Here, four experts with different insights into the field of genomic medicine answer questions about the prospects for using this type of information. Their responses highlight the diverse range of issues that must be addressed — ranging from scientific to ethical and logistical — to ensure that the potential benefits of personal genomic information outweigh the costs to both individuals and societies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fernhoff, P. M. Newborn screening for genetic disorders. Pediatr. Clin. North Am. 56, 505–513 (2009).
Feero, W. G., Guttmacher, A. E. & Collins, F. S. The genome gets personal — almost. JAMA 299, 1351–1352 (2008).
Check Hayden, E. Genome sequencing: the third generation. Nature. 457, 768–769 (2009).
Deyo, R. A. Cascade effects of medical technology. Ann. Rev. Public Health. 23, 23–44 (2002).
McGuire, A. L. & Burke, W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300, 2669–2671 (2008).
International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753–764 (2009).
Pharoah, P. D. P. et al. Polygenes, risk prevention, and targeted prevention of breast cancer. N. Engl. J. Med. 358, 2796–2803 (2008).
Goldstein, D. B., Common genetic variation and human traits. N. Engl. J. Med. 360, 1696–1698 (2009).
Helgadottir, A. et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491–1493 (2007).
McPherson, R. et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488–1491 (2007).
Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nature Genet. 41, 342–347 (2009).
Erdmann, J. et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nature Genet. 41, 280–282 (2009).
Samani, N. J. et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443–453 (2007).
Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genet. 41, 334–341 (2009).
United States Government Accountability Office. Nutrigenetic Testing: Tests Purchased from Four Web Sites Mislead Consumers [online], (2006).
Federal Trade Commission. At-Home Genetic Tests: A Healthy Dose of Skepticism May Be the Best Prescription [online], (2009).
Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science. 308, 385–389 (2005).
Moshfeghi, D. M. & Blumenkranz, M. S. Role of genetic factors and inflammation in age-related macular degeneration. Retina 27, 269–275 (2007).
Mendoza, O. Patient-centered healthcare. Nature Biotech. 17, BV15 (1999).
Stolberg, S. G. A small leap to designer babies. New York Times E7 (1 Jan 2000).
Xu, J. et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 69, 1565–1572 (2009).
Flockhart, D. A., Skaar, T., Berlin, D. S., Klein, T. E. & Nguyen, A. T. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86, 109–113 (2009).
Zheng, S. L. et al. Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol. Biomarkers Prev. 18, 1815–1820 (2009).
Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
Belmont, J. & McGuire, A. L. The futility of genomic counseling: essential role of electronic health records. Genome Med. 1, 48 (2009).
Bodmer, W. & Bonilla, C. Common and rare variants in multifactorial susceptibility to common diseases. Nature Genet. 40, 695–701 (2008).
Schadt, E. E., Friend, S. H. & Shaywitz, D. A. A network view of disease and compound screening. Nature Rev. Drug Discov. 8, 286–295 (2009).
Guttmacher, A. E., Porteous, M. E. & McInerney, J. D. Educating health care professionals about genetics and genomics. Nature Rev. Genet. 8, 151–157 (2007).
Lanie, A. D. et al. Exploring the public understanding of basic genetic concepts. J. Genet. Couns. 13, 305–320 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Kári Stefánsson is an employee of and shareholder in deCODE genetics.
Related links
Rights and permissions
About this article
Cite this article
Guttmacher, A., McGuire, A., Ponder, B. et al. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 11, 161–165 (2010). https://doi.org/10.1038/nrg2735
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrg2735
This article is cited by
-
Factors associated with adherence to BRCA1/2 mutation testing after oncogenetic counseling in long-surviving patients with a previous diagnosis of breast or ovarian cancer
Journal of Community Genetics (2023)
-
GWAS findings improved genomic prediction accuracy of lipid profile traits: Tehran Cardiometabolic Genetic Study
Scientific Reports (2021)
-
Are providers prepared for genomic medicine: interpretation of Direct-to-Consumer genetic testing (DTC-GT) results and genetic self-efficacy by medical professionals
BMC Health Services Research (2019)
-
More than Moore’s Mores: Computers, Genomics, and the Embrace of Innovation
Journal of the History of Biology (2018)
-
Risk for Patient Harm in Canadian Genetic Counseling Practice: It's Time to Consider Regulation
Journal of Genetic Counseling (2017)